Evidence map›Paper›PMID 42850545›Full record

ArticleAIDS and behavior2026

What Do People with HIV Want to Know About Long-Acting Injectable Cabotegravir/Rilpivirine?

Alicia Dawdani, Kaylin V Dance, Moira C McNulty, Xavier A Erguera, Rey Flores, Mollie B Smith, Manami Diaz Tsuzuki, Priyasha Pareek, Laurence Balter, Elizabeth T Montgomery and 7 more

Abstract read
PubMed Publisher
In one paragraph

Article in AIDS and behavior, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Alicia DawdaniSection of Infectious Diseases and Global Health, Department of Medicine, University of Chicago, 5841 S. Maryland Ave, MC 5065, Chicago, IL, 60637, USA.
Kaylin V DanceDivision of Infectious Diseases, Department of Medicine, Emory University School of Medicine, Atlanta, GA, USA.
Moira C McNultySection of Infectious Diseases and Global Health, Department of Medicine, University of Chicago, 5841 S. Maryland Ave, MC 5065, Chicago, IL, 60637, USA. moira.mcnulty@bsd.uchicago.edu.ORCID http://orcid.org/0000-0002-9651-254X
Xavier A ErgueraDepartment of Medicine, University of California, San Francisco, San Francisco, CA, USA.
Rey FloresSection of Infectious Diseases and Global Health, Department of Medicine, University of Chicago, 5841 S. Maryland Ave, MC 5065, Chicago, IL, 60637, USA.
Mollie B SmithDepartment of Medicine, University of California, San Francisco, San Francisco, CA, USA.
Manami Diaz TsuzukiSchool of Medicine, University of California, San Francisco, San Francisco, CA, USA.
Priyasha PareekDivision of Infectious Diseases, Department of Medicine, Emory University School of Medicine, Atlanta, GA, USA.
Laurence BalterDivision of Infectious Diseases, Department of Medicine, Emory University School of Medicine, Atlanta, GA, USA.
Elizabeth T MontgomeryResearch Triangle International, Berkeley, CA, USA.
Mallory O JohnsonDepartment of Medicine, University of California, San Francisco, San Francisco, CA, USA.
John SaucedaDepartment of Medicine, University of California, San Francisco, San Francisco, CA, USA.
Matthew D HickeyDepartment of Medicine, University of California, San Francisco, San Francisco, CA, USA.
Lauren F CollinsDivision of Infectious Diseases, Department of Medicine, Emory University School of Medicine, Atlanta, GA, USA.
Jonathan A ColasantiDivision of Infectious Diseases, Department of Medicine, Emory University School of Medicine, Atlanta, GA, USA.
Kimberly A KoesterDepartment of Medicine, University of California, San Francisco, San Francisco, CA, USA.
Katerina A ChristopoulosDepartment of Medicine, University of California, San Francisco, San Francisco, CA, USA.

Funding

Understanding Patient, Provider, and Systems Stakeholder Attitudes and Preferences to Optimize Implementation of Long-Acting Injectable Antiretrovirals and Maximize Clinical and Public Health ImpactR01MH123396 · NIMH · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI CHRISTOPOULOS, KATERINA A, HICKEY, MATTHEW · 2020 to 2023
$3.2M
NIMH NIH HHS R01 MH123396
6 · The paper itself

Abstract

Transitioning from oral to injectable HIV therapy raises unique considerations. We examined the scope and types of questions that people with HIV (PWH) raised about long-acting cabotegravir and rilpivirine (LA-CAB/RPV). We conducted semi-structured interviews with patients at four urban HIV clinics in San Francisco, Chicago, and Atlanta (n = 131). Two cross-sectional samples were recruited during August 2020 to May 2023: (1) pre-implementation, prior to widespread clinical availability (n = 72); and (2) early adopters of LA-CAB/RPV (n = 59). Each dataset was analyzed separately and comparatively using thematic analysis. Participants were 65% male, 45% Black and 27% Latine with median age of 46 years. Questions clustered into four domains: (1) potential side effects; (2) effectiveness; (3) injection visit logistics; and (4) comparison to other injectable medications. Early adopters emphasized the importance of cultivating broader awareness about LA-CAB/RPV. Findings highlight the need for clear, patient-centered information across multiple domains to support informed decisions about LA-CAB/RPV initiation.

Indexed as

Cabotegravir/rilpivirineHIVLong-acting antiretroviral therapyPatient perspectivesQualitative research

Identifiers

PMID42850545

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.